Рецепт. 2021; : 646-653
Миокардит, ассоциированный с SARS-CoV-2
https://doi.org/10.34883/PI.2021.24.5.004Аннотация
Новая коронавирусная инфекция в настоящей действительности является тем заболеванием, которое уносит миллионы жизней. Вопросы патогенеза и терапии коронавирусной инфекции являются приоритетным направлением. При COVID-19 может наблюдаться фульминантное повреждение миокарда с развитием миокардита. Вирус SARS-CoV-2 следует рассматривать как источник и предиктор повреждения миокарда.
В представленной статье собраны данные по обзору информации, касающейся диагностики и терапии фульминантного миокардита, опосредованного SARS-CoV-2.
Список литературы
1. Ruan Q., Yang K., Wang W. (2020) Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med., vol. 6, pp. 1–4.
2. Caforio A.L., Pankuweit S., Arbustini E. (2013) European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on etiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J., vol. 34 (33), pp. 2636–48.
3. Caforio A.L.P., Curr G., Malipiero S., Marcolongo R. (2017) Iliceto Myocarditis: A Clinical Overview. Cardiol Rep., vol. 19 (7): 63.
4. Xu Z., Shi L., Wang Y. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., vol. 8, no 4, pp. 420–422.
5. Oudit G.Y., Kassiri Z., Jiang C. (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest., vol. 39, no 7, pp. 618–25.
6. Huang C., Wang Y., Li X. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet, vol. 395 (10223), pp. 497–506.
7. Wang D., Li S., Jiang J. (2019) Section of Precision Medicine Group of Chinese Society of Cardiology; Editorial Board of Chinese Journal of Cardiology; Working Group of Adult Fulminant Myocarditis. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci., vol. 62 (2), pp. 187–202.
8. Nishiura H., Linton N.M., Akhmetzhanov A.R. (2020) Initial Cluster of Novel Coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission. J Clin Med., vol. 9 (2), p. 488.
9. Ihdayhid A.R., Chopra S., Rankin J. (2014) Intra-aortic balloon pump: indications, efficacy, guidelines and future directions. Curr Opin Cardiol., vol. 29 (4), pp. 285–92.
10. Okai I., Inoue K., Maruyama M. (2012) Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis. Heart Vessels, vol. 27 (6), pp. 639–42.
11. Wang D., Hu B., Hu C. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. JAMA, vol. 323, no 11, pp. 1061–1069.
12. Goland S., Czer L.S., Siegel R.J. (2008) Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol., vol. 24 (7), pp. 571–4.
13. Drucker N.A., Colan S.D., Lewis A.B. (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation, vol. 89 (1), pp. 252–7.
14. Kishimoto C., Shioji K., Hashimoto T. (2014) Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessels, vol. 29 (3), pp. 336–42.
15. Yu D.Q., Wang Y., Ma G.Z. (2014) Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study. Exp Ther Med., vol. 7 (1), pp. 97–102.
16. Isogai T., Yasunaga H., Matsui H. (2015) Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail, vol. 21 (5), pp. 391–7.
17. Gao Dengfeng (2020) Xi’an Jiaotong University Second Affiliated Hospital Anti-epidemic National Medical Team: High-dose vitamin C-based Jiaotong Program [J]. Available at: http://sn.ifeng.com/a/20200214/84295990.shtm
18. Ojnotkinova O., Maslennikova O., Larina V., Rzhevskaya E., Syrov A., Dedov E., Kryukov E., Esin E., Zhuravleva M., Voevoda M., Demidova T., Achkasov E., Spasskij A., Shahnovich P. Soglasovannaya ekspertnaya poziciya po diagnostike i lecheniyu ful’minantnogo miokardita v usloviyah pandemii COVID-19 [Agreed expert position on diagnostics and treatment of fulminant myocarditis in conditions of COVID-19 pandemic]. Akademiya mediciny i sporta, 1 (2), pp. 28–40.
19. Kozlov I., Tyurin I. (2020) Serdechno-sosudistye oslozhneniya COVID-19 [Cardiovascular complications of COVID-19]. Vestnik anesteziologii i reanimatologii, vol. 17, no 4, pp. 14–22.
20. Driggin E., Madhavan M.V., Bikdeli B. (2020) Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol., vol. 75, no 18, pp. 2352–2371.
21. Long B., Brady W.J., Koyfman A. (2020) Cardiovascular complications in COVID-19. Am. J. Emerg. Med., Apr. 18, pp. 1–4.
Recipe. 2021; : 646-653
Myocarditis Associated with SARS-CoV-2
https://doi.org/10.34883/PI.2021.24.5.004Abstract
New coronavirus infection is really a disease that takes millions of lives. The issues of pathogenesis and therapy of coronаvirus infection are a priority. Fulminant myocardial damage with the development of myocarditis is relevant in COVID-19. SARS-CoV-2 virus should be considered as the source and predictor of myocardial damage.
In this article, there are collected the data from a review of information related to diagnostics and therapy of fulminant myocarditis mediated by SARS-CoV-2.
References
1. Ruan Q., Yang K., Wang W. (2020) Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens. Care Med., vol. 6, pp. 1–4.
2. Caforio A.L., Pankuweit S., Arbustini E. (2013) European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on etiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J., vol. 34 (33), pp. 2636–48.
3. Caforio A.L.P., Curr G., Malipiero S., Marcolongo R. (2017) Iliceto Myocarditis: A Clinical Overview. Cardiol Rep., vol. 19 (7): 63.
4. Xu Z., Shi L., Wang Y. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., vol. 8, no 4, pp. 420–422.
5. Oudit G.Y., Kassiri Z., Jiang C. (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest., vol. 39, no 7, pp. 618–25.
6. Huang C., Wang Y., Li X. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet, vol. 395 (10223), pp. 497–506.
7. Wang D., Li S., Jiang J. (2019) Section of Precision Medicine Group of Chinese Society of Cardiology; Editorial Board of Chinese Journal of Cardiology; Working Group of Adult Fulminant Myocarditis. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci., vol. 62 (2), pp. 187–202.
8. Nishiura H., Linton N.M., Akhmetzhanov A.R. (2020) Initial Cluster of Novel Coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission. J Clin Med., vol. 9 (2), p. 488.
9. Ihdayhid A.R., Chopra S., Rankin J. (2014) Intra-aortic balloon pump: indications, efficacy, guidelines and future directions. Curr Opin Cardiol., vol. 29 (4), pp. 285–92.
10. Okai I., Inoue K., Maruyama M. (2012) Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis. Heart Vessels, vol. 27 (6), pp. 639–42.
11. Wang D., Hu B., Hu C. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. JAMA, vol. 323, no 11, pp. 1061–1069.
12. Goland S., Czer L.S., Siegel R.J. (2008) Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol., vol. 24 (7), pp. 571–4.
13. Drucker N.A., Colan S.D., Lewis A.B. (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation, vol. 89 (1), pp. 252–7.
14. Kishimoto C., Shioji K., Hashimoto T. (2014) Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessels, vol. 29 (3), pp. 336–42.
15. Yu D.Q., Wang Y., Ma G.Z. (2014) Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study. Exp Ther Med., vol. 7 (1), pp. 97–102.
16. Isogai T., Yasunaga H., Matsui H. (2015) Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail, vol. 21 (5), pp. 391–7.
17. Gao Dengfeng (2020) Xi’an Jiaotong University Second Affiliated Hospital Anti-epidemic National Medical Team: High-dose vitamin C-based Jiaotong Program [J]. Available at: http://sn.ifeng.com/a/20200214/84295990.shtm
18. Ojnotkinova O., Maslennikova O., Larina V., Rzhevskaya E., Syrov A., Dedov E., Kryukov E., Esin E., Zhuravleva M., Voevoda M., Demidova T., Achkasov E., Spasskij A., Shahnovich P. Soglasovannaya ekspertnaya poziciya po diagnostike i lecheniyu ful’minantnogo miokardita v usloviyah pandemii COVID-19 [Agreed expert position on diagnostics and treatment of fulminant myocarditis in conditions of COVID-19 pandemic]. Akademiya mediciny i sporta, 1 (2), pp. 28–40.
19. Kozlov I., Tyurin I. (2020) Serdechno-sosudistye oslozhneniya COVID-19 [Cardiovascular complications of COVID-19]. Vestnik anesteziologii i reanimatologii, vol. 17, no 4, pp. 14–22.
20. Driggin E., Madhavan M.V., Bikdeli B. (2020) Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol., vol. 75, no 18, pp. 2352–2371.
21. Long B., Brady W.J., Koyfman A. (2020) Cardiovascular complications in COVID-19. Am. J. Emerg. Med., Apr. 18, pp. 1–4.
